| Serial Number | 98069926 |
| Word Mark | XDC THE BIOCONJUGATION LEADER |
| Filing Date | Monday, July 3, 2023 |
| Status | 819 - SU - REGISTRATION REVIEW COMPLETE |
| Status Date | Wednesday, August 28, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, December 12, 2023 |
| Goods and Services | Custom assembling of materials for others; custom manufacturing of pharmaceuticals; custom manufacturing of drug conjugates; custom production of pharmaceuticals; custom production of biological preparations; custom manufacturing of antibody-drug conjugates; custom manufacturing of chemical reagents; custom manufacturing of pharmaceutical preparations; custom manufacturing of biomedical preparations; custom manufacture of drug conjugates; processing of pharmaceutical preparations; processing or treating of chemical reagents; processing of antibody drugs; custom manufacturing of antibody drugs; processing of biomedical preparations; processing of biotechnology drug |
| Description of Mark | The mark consists of the stylized wording "XDC" to the right of an incomplete oval outline that intersects with another incomplete oval outline. The stylized wording "The Bioconjugation Leader" appears below "XDC". |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| NOT AVAILABLE | "BIOCONJUGATION" |
| Goods and Services | Development of products for others in the field of pharmaceuticals; pharmaceutical drug development services; research and development of new products in the field of pharmaceuticals; biochemical research and development; custom design and development of chemical reagent antibodies and conjugate antibodies; research and development in the pharmaceutical, biomedicine and biotechnology fields; research and development of antibodies; research and development of conjugated antibodies; biomedical research services; development of pharmaceutical preparations and medicines; research and development of antibody-drug conjugates; research and development of drug conjugates; preclinical research and evaluation of new drugs; consulting services in the field of technology development; research and development of new products for others; scientific research and development |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 3, 2023 |
| Primary Code | 040 |
| First Use Anywhere Date | Friday, October 20, 2023 |
| First Use In Commerce Date | Friday, October 20, 2023 |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 3, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | Friday, October 20, 2023 |
| First Use In Commerce Date | Friday, October 20, 2023 |
| Party Name | WuXi XDC Cayman Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Grand Cayman KY1-1104 KY |
| Party Name | WuXi XDC Cayman Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Grand Cayman KY1-1104 KY |
| Event Date | Event Description |
| Thursday, July 6, 2023 | NEW APPLICATION ENTERED |
| Thursday, August 3, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, August 4, 2023 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Tuesday, October 31, 2023 | ASSIGNED TO EXAMINER |
| Friday, November 3, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, November 3, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Friday, November 3, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, November 3, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Friday, November 3, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 22, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, December 12, 2023 | PUBLISHED FOR OPPOSITION |
| Tuesday, December 12, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 6, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, May 29, 2024 | USE AMENDMENT FILED |
| Wednesday, May 29, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Saturday, July 6, 2024 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Sunday, July 7, 2024 | STATEMENT OF USE PROCESSING COMPLETE |
| Wednesday, August 28, 2024 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Wednesday, August 28, 2024 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |